2. Elmer GW, McFarland LV. 2001; Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am. 30:837–854. DOI:
10.1016/S0889-8553(05)70213-2.
Article
6. Buts JP, Dekeyser N, Stilmant C, Delem E, Smets F, Sokal E. 2006; Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res. 60:24–29. DOI:
10.1203/01.pdr.0000220322.31940.29. PMID:
16690953.
Article
7. Fidan I, Kalkanci A, Yesilyurt E, et al. 2009; Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses. 52:29–34. DOI:
10.1111/j.1439-0507.2008.01545.x. PMID:
18627477.
8. Torres J, Bonovas S, Doherty G, et al. 2020; ECCO Guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 14:4–22. DOI:
10.1093/ecco-jcc/jjz180. PMID:
31711158.
9. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. 2008; Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 43:842–848. DOI:
10.1080/00365520801943354. PMID:
18584523.
10. Guslandi M, Mezzi G, Sorghi M, Testoni PA. 2000; Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 45:1462–1464. DOI:
10.1023/A:1005588911207. PMID:
10961730.
11. Bourreille A, Cadiot G, Le Dreau G, et al. 2013; Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol. 11:982–987. DOI:
10.1016/j.cgh.2013.02.021. PMID:
23466709.
Article
12. Lichtenstein L, Avni-Biron I, Ben-Bassat O. 2016; Probiotics and prebiotics in Crohn's disease therapies. Best Pract Res Clin Gastroenterol. 30:81–88. DOI:
10.1016/j.bpg.2016.02.002. PMID:
27048899.
Article
13. Plein K, Hotz J. 1993; Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study. Z Gastroenterol. 31:129–134.
14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. 2002; Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359:1541–1549. DOI:
10.1016/S0140-6736(02)08512-4.
Article
15. O'Sullivan M, O'Morain C. 2006; Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 20:561–573. DOI:
10.1016/j.bpg.2006.03.001. PMID:
16782529.
16. Gasche C, Waldhoer T, Feichtenschlager T, et al. 2001; Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 96:2382–2387. DOI:
10.1111/j.1572-0241.2001.04094.x. PMID:
11513178.
Article
17. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. 1998; Metabolic features of inflammatory bowel disease in a remission phase of the disease activity. J Intern Med. 243:339–347. DOI:
10.1046/j.1365-2796.1998.00254.x. PMID:
9651555.
Article
18. Maaser C, Sturm A, Vavricka SR, et al. 2019; ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 13:144–164. DOI:
10.1093/ecco-jcc/jjy113. PMID:
30137275.
Article
19. D'Haens G, Ferrante M, Vermeire S, et al. 2012; Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 18:2218–2224. DOI:
10.1002/ibd.22917. PMID:
22344983.
20. Boyle RJ, Robins-Browne RM, Tang ML. 2006; Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 83:1256–1447. DOI:
10.1093/ajcn/83.6.1256. PMID:
16762934.
Article
21. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. 1993; Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res. 10:1615–1619. DOI:
10.1023/A:1018924820333. PMID:
8290474.
22. Ford AC, Bernstein CN, Khan KJ, et al. 2011; Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 106:590–600. DOI:
10.1038/ajg.2011.70. PMID:
21407179.
Article